๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography
NCT06025305Coronary Artery Disease, Plaque, Atherosclerotic
Jinling Hospital, China
Observational
2,000
Nanjing
2023-07-01
Recruiting
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
NCT06172205BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
262
Guangzhou
2023-07-01
Recruiting
Short-term Cervical Spinal Cord Stimulation in Patients With Disorders of Consciousness After Intracerebral Hemorrhage
NCT05922644Coma, Stroke
Beijing Tiantan Hospital
Not applicable
344
Beijing
2023-07-01
Active, closed
A Digital Tongue Diagnosis Model for High- and Low-risk Esophagogastroduodenal Varices in Cirrhosis
NCT05979935Esophageal Varices, Liver Cirrhosis, Sublingual Varices, Portal Hypertension
Qilu Hospital of Shandong University
Observational
1,300
Jinan
2023-07-01
By invitation
A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome After Radical Gastrectomy
NCT06707714Metabolic Syndrome, Gastric Cancer
Dong Peng
Observational
150
Chongqing
2023-07-01
By invitation
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
NCT06468943Effects of Chemotherapy, Safety Issues
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2023-07-01
Recruiting
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
NCT05920863Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE
Zhejiang Cancer Hospital
Phase 2
35
Hangzhou
2023-07-01
Not yet open
Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness
NCT05881746Colorectal Carcinoma, Liver Metastases
Fudan University
Not applicable
176
Shanghai
2023-07-01
By invitation
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
NCT05947825PDAC - Pancreatic Ductal Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjing
2023-07-01
Recruiting
The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants
NCT06071403Growth Retardation
Peking University
Observational
416
Xingtai
2023-07-01
Recruiting
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
NCT05919030Esophageal Squamous Cell Carcinoma
Renmin Hospital of Wuhan University
Phase 3
155
Wuhan
2023-07-01
Recruiting
AI-Driven Genotype Prediction Using EHR and Multimodal Data
NCT06791421Genotype
The Eye Hospital of Wenzhou Medical University
Observational
100,000
Guangzhou, Wenzhou
2023-07-01
Recruiting
Microfluidic Chip Method Versus Density Gradient Centrifugation Method on Semen Parameters
NCT05978947Infertility
Professor Ernest Hung-Yu Ng
Not applicable
80
Hong Kong
2023-07-01
Recruiting
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
NCT05904964HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
288
Guangzhou, Shantou, Qionghai
2023-07-01
Recruiting
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
NCT05623267Limited Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2/3
346
Guangzhou
2023-07-01
Recruiting
Safety and Efficacy of NK510 to Treat NSCLC
NCT06097962NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
12
Nanjing
2023-07-01
Recruiting
Efficacy of NA Combined With PEG-IFN-ฮฑ2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B
NCT05922306Hepatitis B, Chronic
Anhui Medical University
Phase EARLY_PHASE1
1,084
Hefei
2023-07
Not yet open
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
NCT05910125Ischemic Stroke
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
472
Guangzhou
2023-07
Recruiting
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
NCT05965115Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Shanghai Zhongshan Hospital
Observational
10,000
Shanghai
2023-07
Not yet open
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
NCT05841849Breast Cancer, Chemotherapy-induced Nausea and Vomiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
1,028
Hanzhou
2023-07
Active, closed
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
551
Beijing
2023-06-30
Recruiting
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke
NCT05799326Acute Ischemic Stroke
Yi Yang
Not applicable
100
Changchun
2023-06-30
Recruiting
Pegylated Interferon ฮฑ-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
NCT05870475Polycythemia Vera
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
94
Tianjin
2023-06-30
Recruiting
A Phase Ia/Ib Open Label๏ผŒClinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NCT05868876Advanced Malignant Tumors
Akeso
Phase 1
205
Tianjin
2023-06-29
Recruiting
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
NCT05962840ANCA Associated Vasculitis
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-06-29
Recruiting
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
NCT05894018Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors
Fujun Zhang
Phase 2
32
Guangzhou
2023-06-29
Recruiting
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
NCT05940896Solid Tumor
RemeGen Co., Ltd.
Phase 1
24
Jinan
2023-06-29
Recruiting
Long-term Success Rate of Transvaginal Mesh for the Treatment of Pelvic Organ Prolapse: The Extended RCT Study
NCT05938881Pelvic Organ Prolapse
Peking Union Medical College Hospital
Observational
336
Foshan, Guangzhou, Changsha, Wuxi, Jinan, Xiโ€™an, Chengdu, รœrรผmqi
2023-06-29
Recruiting
Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population
NCT05725096Statin, Cardiovascular Risk Factors, Primary Prevention, Adherence, Medication
Zhang longjiang,MD
Not applicable
3,400
Nanjing
2023-06-28
Recruiting
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT05913804Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2023-06-28
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche
Phase 3
2,000
Hefei, Beijing, Zunyi, Wuhan, Xuzhou, Pingxiang, Shanghai, Zigong
2023-06-28
Recruiting
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
NCT05806099Non-Hodgkin's Lymphoma
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
132
Beijing
2023-06-28
Active, closed
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
NCT05751187Non-squamous NSCLC
Shanghai Chest Hospital
Phase 2
54
Shanghai
2023-06-27
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Novartis Pharmaceuticals
Phase 1
123
Beijing, Guangzhou
2023-06-27
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
NCT05627063Solid Tumor
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Active, closed
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
NCT05870319Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Guangzhou
2023-06-26
Active, closed
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
NCT06126081Heart Failure, Left Bundle Branch Pacing
Fu Wai Hospital, Beijing, China
Not applicable
36
Beijing, Nanjing
2023-06-26
Active, closed
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
NCT05756972NSCLC
Biotheus Inc.
Phase 2
64
Guangzhou
2023-06-26
Active, closed
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
NCT06191354Spinal Muscular Atrophy 1
Kun Sun
Not applicable
12
Chengdu, Shanghai
2023-06-25
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
NCT05803018Gynecological Malignant Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
38
Shanghai
2023-06-25
Active, closed
Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids
NCT06244251Uterine Fibroid, Uterine Sarcoma, Uterine Leiomyosarcoma
West China Second University Hospital
Not applicable
5,000
Chengdu
2023-06-24
Recruiting
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
NCT05925023Warm Autoimmune Hemolytic Anemia
Peking Union Medical College Hospital
Not applicable
22
Beijing
2023-06-24
Recruiting
Postoperative Effects of Different Enterostomy Approaches
NCT05853094Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant
Fudan University
Not applicable
300
Shanghai
2023-06-23
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Jilin City, Shanghai
2023-06-22
Recruiting
Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer
NCT06446050Advanced Colorectal Cancer
Shanghai East Hospital
Phase EARLY_PHASE1
30
Shanghai
2023-06-21
Recruiting
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
NCT05475613Liver Transplantation, Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
59
Guangzhou
2023-06-21
Recruiting
Omission of SLNB in CN0 Early Breast Cancer
NCT05935150Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node
The First Affiliated Hospital with Nanjing Medical University
Not applicable
311
Nanjing
2023-06-21
Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
NCT05914545Advanced and Metastatic Solid Tumor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
121
Hangzhou, Shanghai, Xuzhou
2023-06-21
Recruiting
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
NCT05747729Neuroendocrine Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
60
Wuhan
2023-06-21
Recruiting
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
NCT06168786Colorectal Cancer
Huazhong University of Science and Technology
Phase 2
40
Wuhan
2023-06-20
Recruiting
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
NCT07102004Advanced/Metastatic Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
515
Beijing
2023-06-20
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Recruiting
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
NCT05956639Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University
Phase 3
100
Nanjing
2023-06-20
Active, closed
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Recruiting
Doxycycline for Helicobacter Pylori Rescue Treatment
NCT05874570Helicobacter Pylori Infection
Shanghai Jiao Tong University School of Medicine
Phase 4
368
Shanghai
2023-06-20
Recruiting
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT05965557Lung Cancer
Geneplus-Beijing Co. Ltd.
Observational
100
Shanghai
2023-06-19
Recruiting
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
NCT06013618Neuroblastoma
Sun Yat-Sen University Cancer Center
Phase 2
120
Guangzhou
2023-06-19
Recruiting
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
NCT05342194Intrahepatic Cholangiocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
480
Shanghai
2023-06-19
Recruiting
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500Medullary Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
360
Hefei, Beijing, Lanzhou, Nanning, Shijiazhuang, Tianjin, Zhengzhou, Wuhan
2023-06-19
Recruiting
A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota
NCT06266897Endometriosis
Zhujiang Hospital
Observational
500
Guangzhou
2023-06-18
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897Crohn's Disease
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Active, closed
Application of Sticky Bone and Bio-Oss Collagen in Alveolar Ridge Preservation
NCT05902689Alveolar Bone Resorption
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
42
Hangzhou
2023-06-15
Recruiting
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
NCT06252792Multiple Myeloma, First Relapse
FengYan Jin
Observational
50
Changchun
2023-06-15
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
NCT05901558Autism Spectrum Disorder, Therapy
Children's Hospital of Fudan University
Not applicable
110
Shanghai
2023-06-15
Recruiting
Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
NCT07041320Lung Cancer (NSCLC), Elderly (People Aged 65 or More)
Anhui Chest Hospital
Observational
40
Hefei
2023-06-15
Recruiting
Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer
NCT05904665Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation
Fudan University
Not applicable
584
Shanghai
2023-06-15
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
GlaxoSmithKline
Phase 1/2
123
Suzhou
2023-06-14
Recruiting
Helical Tomotherapy in Multiple Myeloma
NCT05970198Multiple Myeloma
Fuling Zhou
Not applicable
58
Wuhan
2023-06-14
Recruiting
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
NCT05940532Carcinoma, Non-Small-Cell Lung
Hunan Cancer Hospital
Phase 2
41
Changsha
2023-06-14
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
NCT06343064Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 1/2
156
Shanghai
2023-06-13
Recruiting
DCNN Developed for Detection and Assessing the Perfusion of PTG
NCT05869058Thyroidectomy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
300
Guangzhou
2023-06-13
Recruiting
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
NCT07350707Cushing s Syndrome
Peking Union Medical College Hospital
Phase 1/2
160
Beijing
2023-06-12
Recruiting
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
NCT06908291Breast Masses, Breast Cancer, Breast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital
Not applicable
500
Beijing
2023-06-12
Recruiting
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
NCT05892354Locally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Not applicable
190
Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2023-06-12
Not yet open
Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
NCT05890339Stomach Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
216
Guangzhou
2023-06-10
Recruiting
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis
NCT06031610Carotid Artery Stenosis, Cerebral Small Vessel Diseases
Zhejiang Provincial People's Hospital
Observational
1,000
Hangzhou
2023-06-10
Recruiting
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
NCT05794971Colorectal Cancer Liver Metastases, Regorafenib
Sun Yat-sen University
Phase 3
126
Guangdong
2023-06-10
Recruiting
Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT05740319Irritable Bowel Syndrome
Shanghai Zhongshan Hospital
Not applicable
102
Shanghai
2023-06-10
Recruiting
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
NCT05912816Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
RenJi Hospital
Phase 2
20
Shanghai
2023-06-10
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
NCT05943379NMIBC
RemeGen Co., Ltd.
Phase 2
85
Beijing
2023-06-08
Recruiting
Safety and Efficacy of Ceraโ„ข Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123Osteosarcoma, Sarcoma
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
Cohort Study of Chronic Heart Failure
NCT05960890Heart Failure
Jiangsu Taizhou People's Hospital
Not applicable
1,000
Taizhou
2023-06-08
Recruiting
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
NCT05883852HER2 Positive Early Breast Cancer
Fudan University
Phase 3
1,406
Shanghai
2023-06-07
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Recruiting
Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction
NCT05847478Obesity, Childhood
Children's Hospital of Fudan University
Not applicable
240
Shanghai
2023-06-07
Active, closed
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression
NCT06939452Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia
Phase 2
37
Zhengzhou
2023-06-07
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Recruiting
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
NCT06125327Idiopathic Pulmonary Fibrosis
Guangzhou JOYO Pharma Co., Ltd
Phase 2/3
210
Beijing
2023-06-06
Recruiting
Effect of Lidocaine on Postoperative Pain and Long-term Survival in Elderly Patients Undergoing Colorectal Surgery
NCT06405776Colorectal Cancer
West China Hospital
Not applicable
276
Sichuan
2023-06-05
Recruiting
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
NCT05991336Transfusion-dependent Beta-Thalassemia, Gene Therapy
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Tianjin
2023-06-05
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Rows per page Showing 15101–15200 of 19052
Previous 150 151 152 153 154 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=152

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.